Efuels Technologies Ltd

Project Title:

Power-to-gas via microbial electrosynthesis of methane from biogenic CO2.


Acronym:

Efuels


Call:

Innovate UK Fast Start: Innovation


Start Date:

01/11/2022


Duration:

6 months


Grant Amount:

£50,000


Our Role:

Review


Through SETsquared’s Scale-Up Programme, RedKnight, has supported Efuels Technologies Ltd with its successful application to Innovate UK’s Fast Start competition, helping the innovative start-up to secure £50k.

 

SETsquared’s Scale-Up Programme supports businesses to raise public funding and private equity. RedKnight is one of several approved grant-writing consultancies on the programme and provided Efuels with grant-writing services to secure this bid.

Efuels Technologies is developing a novel power-to-methane technology to store renewable energy within the existing natural gas infrastructure. If the technology is successfully upscaled, energy generators could use curtailed electricity to convert biogenic CO2 into synthetic natural gas. The Fast Start innovation funding will allow the company, in collaboration with the University of Surrey, to build evidence of market validation and a bench-scale prototype of the technology.

Dr Jose Batista, Founder of Efuels Technology Ltd said, “The connection of the electricity, and gas network will play a pivotal role in the UK’s transition to net zero. The UK is nowadays writing a new chapter of the grapple against climate change. Today, wind farms provide more than 21% of the total power generated. This is fantastic but the intermittency in wind power generation has led to a big problem. Negative electricity prices are already reported during windy days when supply surpasses demand.  As soon as the grid exceeds capacity, wind farms must switch off to avoid collateral damage to the network. However, they are compensated via a constraint payment, which is passed onto consumers’ energy bills. It is known consumers have paid over £650m worth of constraint payments to wind farms. The government now wants 50 gigawatts (GW) of the UK's electricity from offshore wind by the end of the decade. If this problem remains unsolved, consumers will face larger costs in the energy bill”.

Efuels Technologies proposes a simple but challenging solution. It aims to leverage the 7,660 km of existing gas pipelines across the UK to store and transport energy surpluses from wind farms. It achieves this by converting excess renewable power into methane, which can be injected into the gas network with no regulatory barriers. The technology could create a unique bi-directional link between the electricity and gas industry to unlock more flexibility and reliability of supply into the energy market.

Through SETsquared’s Scale-Up Programme, RedKnight, has supported Efuels Technologies Ltd with its successful application to Innovate UK’s Fast Start competition, helping the innovative start-up to secure £50k.

 

SETsquared’s Scale-Up Programme supports businesses to raise public funding and private equity. RedKnight is one of several approved grant-writing consultancies on the programme and provided Efuels with grant-writing services to secure this bid.

Efuels Technologies is developing a novel power-to-methane technology to store renewable energy within the existing natural gas infrastructure. If the technology is successfully upscaled, energy generators could use curtailed electricity to convert biogenic CO2 into synthetic natural gas. The Fast Start innovation funding will allow the company, in collaboration with the University of Surrey, to build evidence of market validation and a bench-scale prototype of the technology.

Dr Jose Batista, Founder of Efuels Technology Ltd said, “The connection of the electricity, and gas network will play a pivotal role in the UK’s transition to net zero. The UK is nowadays writing a new chapter of the grapple against climate change. Today, wind farms provide more than 21% of the total power generated. This is fantastic but the intermittency in wind power generation has led to a big problem. Negative electricity prices are already reported during windy days when supply surpasses demand.  As soon as the grid exceeds capacity, wind farms must switch off to avoid collateral damage to the network. However, they are compensated via a constraint payment, which is passed onto consumers’ energy bills. It is known consumers have paid over £650m worth of constraint payments to wind farms. The government now wants 50 gigawatts (GW) of the UK's electricity from offshore wind by the end of the decade. If this problem remains unsolved, consumers will face larger costs in the energy bill”.

Efuels Technologies proposes a simple but challenging solution. It aims to leverage the 7,660 km of existing gas pipelines across the UK to store and transport energy surpluses from wind farms. It achieves this by converting excess renewable power into methane, which can be injected into the gas network with no regulatory barriers. The technology could create a unique bi-directional link between the electricity and gas industry to unlock more flexibility and reliability of supply into the energy market.



Thermetrix Ltd

Project Title:

A home device and cloud portal for diabetic foot ulcer monitoring


Acronym:

PODIUM


Call:

SME Instrument – Phase 1


Start Date:

01/01/2019


Duration:

6 months


Grant Amount:

€50,000 (ca. £44,186.5)


Our Role:

Bid Writing


Funded by the SME Instrument within the H2020 programme, Thermetrix’s disruptive technology PODIUM uses a combination of thermochromic liquid crystal sheet and high-res cameras, to provide a state-of-the-art diabetic foot monitor that can provide accurate early warning on the formation of Diabetic Foot Ulcers (DFUs).

 

The thermal patterns so picked up by PODIUM will be transmitted to a cloud portal helping patients, family and medical staff to detect and immediately treat conditions before the onset of ulceration. In this way, stress and inflammation can be reduced, tissue damage limited and the foot will return to normal. Critically, up to 80% of DFUs may be avoided.

Funded by the SME Instrument within the H2020 programme, Thermetrix’s disruptive technology PODIUM uses a combination of thermochromic liquid crystal sheet and high-res cameras, to provide a state-of-the-art diabetic foot monitor that can provide accurate early warning on the formation of Diabetic Foot Ulcers (DFUs).

 

The thermal patterns so picked up by PODIUM will be transmitted to a cloud portal helping patients, family and medical staff to detect and immediately treat conditions before the onset of ulceration. In this way, stress and inflammation can be reduced, tissue damage limited and the foot will return to normal. Critically, up to 80% of DFUs may be avoided.



Integrated Compound Semiconductors

Project Title:

Monolithically Integrated Detectors for Next Generation Communication Applications.


Acronym:

MISCA


Call:

Eureka-Eurostars


Start Date:

01/11/2018


Duration:

24 months


Grant Amount:

€623,812 (ca. £560,145)


Our Role:

Bid Writing


Global IP traffic will increase 3x over the next 5 years to 3.3ZB pa (CAGR 24%), having increased 127x from 2005, creating an enormous market for fibre optic communications components. The EU has built a significant proportion of GDP on digital activities. The datacentre infrastructure required to deliver such services must embrace step changes in data rate improvements to keep pace with demand, but require reliable, mass produced, high quality optical transceivers to achieve this aim.

MISCA aims to lever semiconductor material integration to deliver disruptive, scalable component platforms, addressing demands of next generation telecommunications and datacommunications optical infrastructure. Project partners will use intelligent monolithic integration of compound semiconductor materials platforms to deliver high-speed detector solutions with co-optimised RF and optical performance.

Global IP traffic will increase 3x over the next 5 years to 3.3ZB pa (CAGR 24%), having increased 127x from 2005, creating an enormous market for fibre optic communications components. The EU has built a significant proportion of GDP on digital activities. The datacentre infrastructure required to deliver such services must embrace step changes in data rate improvements to keep pace with demand, but require reliable, mass produced, high quality optical transceivers to achieve this aim.

MISCA aims to lever semiconductor material integration to deliver disruptive, scalable component platforms, addressing demands of next generation telecommunications and datacommunications optical infrastructure. Project partners will use intelligent monolithic integration of compound semiconductor materials platforms to deliver high-speed detector solutions with co-optimised RF and optical performance.



Optibrium

Project Title:

A Next-Generation Platform for Novel Drug Discovery Using Deep Learning of ADMET Properties.


Acronym:

DeepADMET


Call:

Innovate UK Health & Life Sciences


Start Date:

01/09/2018


Duration:

24 months


Grant Amount:

£819,988


Our Role:

Bid Writing


DeepADMET aims to create a "next generation" platform providing novel methods for compound selection and design for drug discovery purposes, building on Optibrium's current software, StarDropTM.

 

Through expanding the range of ADMET properties that can be modelled and improving their reliability by applying modern 'deep learning' methods, Optibrium can improve the accuracy and applicability of these models.

 

Proof-of-concept work indicates their methods provide a unique advantage over 'off-the-shelf' deep learning methods when applied to sparse, uncertain data of the type found in drug discovery.

DeepADMET aims to create a "next generation" platform providing novel methods for compound selection and design for drug discovery purposes, building on Optibrium's current software, StarDropTM.

 

Through expanding the range of ADMET properties that can be modelled and improving their reliability by applying modern 'deep learning' methods, Optibrium can improve the accuracy and applicability of these models.

 

Proof-of-concept work indicates their methods provide a unique advantage over 'off-the-shelf' deep learning methods when applied to sparse, uncertain data of the type found in drug discovery.



Bond Digital Health Solutions

Project Title:

A digital solution for patient-centred management of Chronic Obstructive Pulmonary Disease


Acronym:

Metis


Call:

Innovate UK Precision Medicine


Start Date:

01/07/2018


Duration:

6 months


Grant Amount:

£68,583


Our Role:

Bid Writing


Through Metis, Bond Digital Health Solutions aim to create a wearable technology that can provide a digital solution to the current void that exists between patients suffering from Chronic Obstructive Pulmonary Disease (COPD) and their doctors. Such “clinical whitespace” often causes a dramatic loss of relevant patient data which could be better used to provide more effective COPD management.

Thanks to this grant, Bond will be able to further develop the product which will equip medical practitioners with independent, accurate analysis of patient data providing valuable, comprehensive insights and evidence-based care.

Through Metis, Bond Digital Health Solutions aim to create a wearable technology that can provide a digital solution to the current void that exists between patients suffering from Chronic Obstructive Pulmonary Disease (COPD) and their doctors. Such “clinical whitespace” often causes a dramatic loss of relevant patient data which could be better used to provide more effective COPD management.

Thanks to this grant, Bond will be able to further develop the product which will equip medical practitioners with independent, accurate analysis of patient data providing valuable, comprehensive insights and evidence-based care.



TALK

Project Title:

International impact of TALK©: a simple and practical approach to multi-professional structured feedback and debriefing, to be used after unplanned learning events in clinical environments.


Acronym:

TALK


Call:

H2020 – Marie Sklodowska Curie Actions (Research & innovation Staff Exchange)


Start Date:

01/06/2017


Duration:

36 months


Grant Amount:

€274,500


Our Role:

Bid Writing


The TALK project aims to guide multi-professional clinical teams learning and improving quality of patient care and patient safety together.

 

The project has contributed to parallel implementation processes in specified units across the 3 participating countries and included research to better understand the benefits of structured debriefing and organisational culture.

Finally, using the data generated from the research study, the tool has been implemented across all participating partners and its impact is going to be assessed.

The TALK project aims to guide multi-professional clinical teams learning and improving quality of patient care and patient safety together.

 

The project has contributed to parallel implementation processes in specified units across the 3 participating countries and included research to better understand the benefits of structured debriefing and organisational culture.

Finally, using the data generated from the research study, the tool has been implemented across all participating partners and its impact is going to be assessed.



IMSPEX

Project Title:

A rapid, non-invasive, cost-effective, analytical device for bacterial or viral infection diagnosis through ultra-high sensitivity breath analysis.


Acronym:

BreathSpec


Call:

H2020 – Fast Track to Innovation


Start Date:

01/05/2017


Duration:

27 months


Grant Amount:

€2.37m


Our Role:

Bid Writing & Project Management


The BreathSpec project aims to develop a rapid, non-invasive device that can diagnose bacterial or viral infections through ultra-high sensitivity breath analysis.

 

Once developed the BreathSpec device will help reduce the development of anti-bacterial resistance and alleviate the growing problem of antimicrobial resistance (AMR) through improved diagnosis of antibiotic treatment.

 

The device will also reduce the scientific, clinical and financial challenges associated with the development of new antibiotics.

The BreathSpec project aims to develop a rapid, non-invasive device that can diagnose bacterial or viral infections through ultra-high sensitivity breath analysis.

 

Once developed the BreathSpec device will help reduce the development of anti-bacterial resistance and alleviate the growing problem of antimicrobial resistance (AMR) through improved diagnosis of antibiotic treatment.

 

The device will also reduce the scientific, clinical and financial challenges associated with the development of new antibiotics.



Iceni Diagnostics

Project Title:

A Carbohydrate Diagnostic for the Detection of Norovirus.


Acronym:

CADDNOR


Call:

Innovate UK Health Bio-Medical Catalyst


Start Date:

01/02/2017


Duration:

12 months


Grant Amount:

£96,952


Our Role:

Bid Writing


The CADDNOR project aims to develop a point of care (POC) diagnostics and carbohydrate-based therapeutics, focused on the detection of Norovirus.

 

The developed assay uses glyconanoparticle technology with potential for replacing molecular technologies and immunodiagnostics – a major shift in analytical approach.

 

The use of carbohydrates instead of antibodies as the recognition mechanism has several advantages including their production using industrial scale, cost-effective chemoenzymatic synthesis which addressed the call topic.

The CADDNOR project aims to develop a point of care (POC) diagnostics and carbohydrate-based therapeutics, focused on the detection of Norovirus.

 

The developed assay uses glyconanoparticle technology with potential for replacing molecular technologies and immunodiagnostics – a major shift in analytical approach.

 

The use of carbohydrates instead of antibodies as the recognition mechanism has several advantages including their production using industrial scale, cost-effective chemoenzymatic synthesis which addressed the call topic.